UNSPSC 51392201: Alinidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H13Cl2N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7IDJ8DS1D, chemically known as 2-(n-allyl-n-(2,6-dichlorophenyl)amino)-2-imidazoline but generally known as alinidine, which bears US NIH Compound Identifier 36354. Alinidine most often comes in base and hydrobromide forms. European Medicines Agency schedules Alinidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05330MIG.

UNSPSC 51392201 Alinidine is a Commodity code that nominally refers to a specific pharmaceutical compound, but recent state and local procurement activity under this code shows little alignment with the pharmaceutical classification. The single recent opportunity on record is Seminole County, Florida's IFB 60459723LAS, which solicits Naloxone and Safe Drug Deactivation Systems—a mismatch with the code's stated scope. The procurement seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for community health initiatives, with quarterly deliveries and a two-year initial term plus one-year renewal option. Vendors must submit bids electronically, include all shipping and delivery costs in pricing, maintain drug-free workplace and E-Verify compliance, carry workers' compensation and general liability insurance, and accept a three-month probationary termination clause. The contract is potentially FEMA-funded, triggering additional federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act.

The code shows minimal recent state and local activity; only the Seminole County procurement is documented in the opportunities block. The IFB posted June 30, 2026, with a response deadline of July 26, 2023—a date inconsistency in the source that suggests data lag. Geographic activity is limited to Florida based on available records. The mismatch between the Commodity code's pharmaceutical framing and the actual procurement of naloxone/deactivation systems suggests either a cataloging error or that this code designation rarely surfaces in state and local contracts. Business development professionals evaluating this code should treat the activity signal as weak and verify current procurement patterns before committing pursuit resources.